Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASTLE phase II carboplatin plus nab-paclitaxel rechallenge in NSCLC with interstitial lung disease
jRCTs031240743Phase 2Recruiting
- Sponsor
- Chiba University Hospital
- Start
- Jun 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD), sponsored by Chiba University Hospital. Primary endpoint: 3-month progression-free survival without acute exacerbation of interstitial lung disease rate. Started Jun 2025; status: recruiting.
02
Drugs
carboplatinpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)interstitial lung disease (ILD)
Beyond the preview
Go deeper on jRCTs031240743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240743.